MyMedR

Choriocarcinoma--a reappraisal

Sen DK

Med J Malaysia, 1979 Jun;33(4):286-8.

PMID: 522737

Matched MeSH terms: Choriocarcinoma/epidemiology*

MicroRNA profiling in complete and partial hydatidiform moles

Chia WK, Yeoh HXY, Mustangin M, Khong TY, Wong YP, Tan GC

Malays J Pathol, 2023 Dec;45(3):353-362.

PMID: 38155377

INTRODUCTION: Hydatidiform mole is one of the gestational trophoblastic disease and comprises complete (CM) and partial moles (PM), which carries a risk of developing persistence disease, invasive mole or choriocarcinoma. MicroRNAs (miRNAs) have been discovered in various tissues, including neoplastic tissues. Its role in the pathogenesis of molar pregnancy or as biomarkers are still largely uncertain. The aim of this study is to identify the differentially expressed miRNAs in CM and PM.

MATERIALS AND METHODS: Using next-generation sequencing, the miRNAs profiles of CM (n=3) and PM (n=3) moles, including placenta of non-molar abortus (n=3) as control were determined. The differentially expressed miRNAs between each group were analysed. Subsequently, bioinformatics analysis using miRDB and Targetscan was utilised to predict target genes.

RESULTS: We found 10 differentially expressed miRNAs in CMs and PMs, compared to NMAs, namely miR- 518a-5p, miR-423-3p, miR-503-5p, miR-302a-3p, and miR-1323. The other 5 miRNAs were novel, not listed in the known database. The 3 differentially expressed miRNAs in CMs were predicted to commonly target ZTBT46 and FAM73B mRNAs.

DISCUSSION: miR-518 was consistently observed to be downregulated in CM versus PM, and CM versus NMA. Further bioinformatic analysis to provide insight into the possible role of these miRNAs in the pathogenesis of HMs, progression of disease and as potential diagnostic biomarkers as well as therapeutic targets for HMs is needed.

Matched MeSH terms: Choriocarcinoma*

Prophylaxis against choriocarcinoma

Sivanesaratnam V, Ng KH

Med J Malaysia, 1977 Mar;31(3):229-31.

PMID: 904517

Matched MeSH terms: Choriocarcinoma/prevention & control*

Factors affecting prognosis of choriocarcioma

Chan DP

Med J Malaya, 1965 Sep;20(1):29-35.

PMID: 4221408

Matched MeSH terms: Choriocarcinoma*

CHORIOCARCINOMA

KIM CK

Med J Malaysia, 1964 Dec;19:140-4.

PMID: 14279237

Matched MeSH terms: Choriocarcinoma*

Fulltext Perforating invasive mole masquerading as an ovarian tumour--case report

Chandran R, Tham KY, Rose I

Med J Malaysia, 1991 Sep;46(3):255-8.

PMID: 1839922

An invasive mole causing uterine perforation is a rare occurrence. We describe below a case with an unusual presentation which was mistaken for an ovarian tumour. The difficulty in diagnosis and the need for a high index of suspicion is highlighted.

Matched MeSH terms: Choriocarcinoma/complications; Choriocarcinoma/pathology; Choriocarcinoma/therapy

ABO blood group in trophoblastic disease

Dawood MY, Teoh ES, Ratnam SS

J Obstet Gynaecol Br Commonw, 1971 Oct;78(10):918-23.

PMID: 5111899

Matched MeSH terms: Choriocarcinoma/blood*; Choriocarcinoma/drug therapy; Choriocarcinoma/mortality

The management of gestational trophoblastic disease in developing countries such as Malaysia

Sivanesaratnam V

Int J Gynaecol Obstet, 1998 Apr;60 Suppl 1:S105-9.

PMID: 9833622 DOI: 10.1016/S0020-7292(98)80012-X

Gestational trophoblastic disease is a common gynaecological problem in Malaysia. The incidence of molar pregnancy is 2.8 per 1000 deliveries, being more common amongst the Chinese. The preferred method of evacuation is suction curettage; complete evacuation of the uterus was not achieved at the first attempt in 25 per cent of cases. Partial moles in our centre comprised 30 per cent of all moles. This is potentially malignant and needs follow-up for a complete mole. In the management of an invasive mole, chemotherapy should not be withheld in the presence of metastases and failure of regression of hCG. The role of prophylactic hysterectomy and prophylactic chemotherapy in the management of molar pregnancy is discussed "Selective preventive chemotherapy" in patients at "risk" appears appropriate. Chemotherapy remains the main modality of treatment for gestational trophoblastic tumours (GTT). We categorised our patients into low, medium and high-risk groups; survivals were 100, 98, and 61.7 percent respectively. These patients when categorised according to FIGO staging had survivals of 100, 80, 78.6 and 68.2 per cent respectively for stages 1, 2, 3 and 4 respectively. The reasons for the poor survival in the 'high-risk' group are discussed. Colour doppler blood flow studies are now being carried out; its role needs further evaluation. Surgery and radiotherapy have only a limited role in the management of these cases.

Matched MeSH terms: Choriocarcinoma/prevention & control

Fulltext Post-hysterectomy choriocarcinoma with pulmonary and renal metastases

Thanikasalam K

Med J Malaysia, 1991 Jun;46(2):187-91.

PMID: 1839425

The propensity of choriocarcinoma to metastasize to lungs, liver and brain is well known. Though theoretically metastases are possible to anywhere in the body, renal metastases are rare. A 56 year old Malay woman who had total abdominal hysterectomy in 1985 for molar pregnancy presented with haemoptysis and dyspnea in 1990. Examination showed she had choriocarcinoma with pulmonary and renal metastases.

Matched MeSH terms: Choriocarcinoma/secondary*

Choriocarcinoma--an unusual case

Khoo KE

Med J Malaysia, 1978 Dec;33(2):156-7.

PMID: 755169

Matched MeSH terms: Choriocarcinoma/complications*

Malignant tumours in Malaya

Ahluwalia HS, Duguid JB

Br. J. Cancer, 1966 Mar;20(1):12-5.

PMID: 5949191

Matched MeSH terms: Choriocarcinoma/epidemiology

Unusual presentation of chorion epithelioma malignum

Subramanyam C, Lal M

Med J Malaya, 1970 Jun;24(4):306-7.

PMID: 4248354

Matched MeSH terms: Choriocarcinoma/pathology*

Fulltext Hydatidiform molar pregnancy in Malaysian women: a histopathological study from the University Hospital, Kuala Lumpur

Cheah PL, Looi LM, Sivanesaratnam V

Malays J Pathol, 1993 Jun;15(1):59-63.

PMID: 8277792

A review of gestational trophoblastic disease diagnosed at the Department of Pathology, University Hospital, Kuala Lumpur from January 1989 to December 1990 using established histological criteria showed 25 complete hydatidiform moles (CHM), 11 partial hydatidiform moles (PHM), 1 invasive mole and 2 choriocarcinoma. The ages of the patients with CHM ranged from 21 to 43 years (mean = 28.5 years) and PHM 20 to 33 years (mean = 27.5 years). The invasive mole occurred in a 42-year-old Malay woman. The two patients with choriocarcinoma were both Chinese and 41 and 46-years old respectively. During the same period, 1,062 non-molar abortions and 13,115 births, inclusive of livebirths and stillbirths were recorded at the University Hospital. The incidence rate of hydatidiform moles was thus estimated to be 1:384 pregnancies. PHM constituted 30% of all molar pregnancies. Hydatidiform moles occurred among the Malays, Chinese and Indians at the rate of 2.43, 2.66 and 3.29 per 1,000 pregnancies respectively. It appears that hydatidiform molar pregnancy has the highest prevalence among the Indians, a finding similar to an earlier Singapore study.

Matched MeSH terms: Choriocarcinoma/epidemiology; Choriocarcinoma/pathology

Management of the pregnant mother with malignant conditions

Sivanesaratnam V

Curr Opin Obstet Gynecol, 2001 Apr;13(2):121-5.

PMID: 11315864

A malignancy discovered in pregnancy is often difficult to manage; the optimal maternal therapy has to be balanced with the fetal well-being. Generally, the cancer is managed as though the patient is not pregnant. For the various site-specific cancers, surgery is the main modality of treatment; this should be individualized. Chemotherapeutic agents are highly teratogenic in the first trimester, with some adverse effects when used after 12 weeks' gestation. The overall survival rate for pregnancy-associated breast cancer is poor; the reasons for this are discussed. For cervical cancer, delivery by caesarean section appears to be the method of choice, with significantly better survival rates compared with those who deliver vaginally. Other gynaecological and non-gynaecological malignancies are discussed.

Matched MeSH terms: Choriocarcinoma/diagnosis; Choriocarcinoma/therapy

Cerebral metastases from choriocarcinoma. Results of chemotherapy

Sen DK, Sivanesaratnam V, Chuah CY, Ch'ng SL, Singh J, Paramsothy M

Acta Obstet Gynecol Scand, 1987;66(5):425-8.

PMID: 3425244

Of 36 cases of choriocarcinoma treated at the University Hospital Kuala Lumpur during 1980-84 inclusive, 6 patients were found to have cerebral metastases. Intrathecal methotrexate and combination chemotherapy were started in all cases, with monitoring of tumor growth by serial beta-HCG assays and CT scanning of brain and lung. Chemotherapy was reduced because of severe toxicity in 2 patients, one of whom received radiotherapy to the brain. Four patients (66%) have now been in remission for 2.5-6 years. Two did not respond to therapy and died. The factors involved in therapy and response are discussed.

Matched MeSH terms: Choriocarcinoma/blood; Choriocarcinoma/drug therapy*; Choriocarcinoma/mortality

All-trans retinoic acid (atra) inhibits telomerase expression of BeWo choriocarcinoma cell (ATCC CCL-98)

Tatit NS, Kevin P

Med J Malaysia, 2019 12;74(6):504-508.

PMID: 31929476

INTRODUCTION: Choriocarcinoma is malignant cancer originating from placental trophoblast. The incidence of this cancer is estimated at 0.57-1.1 per 1000 births in the United States of America, Australia, Europe, and New Zealand. The rate is much higher in South East Asia and Japan with two occurrences per a thousand births. Telomerase activity is an important part of the apoptotic process. Increased telomerase activity will result in cellular immortality and poor prognosis in cancer. Vitamin A possess an essential role in cell proliferation and differentiation. One of the active metabolites of vitamin A is All-Trans Retinoic Acid (ATRA).

METHODS: In this study, we examined the role of ATRA against telomerase activity in choriocarcinoma cell. This cell was derived from BeWo cell line (ATCC CCL-98) and were given different doses of ATRA.

RESULTS: From this study, Choriocarcinoma cell that was given ATRA in dosage of 50μg/ml inhibit telomerase activity by extending the cycle time of 39.51±0.09, compared to the control group with a cycle time of 37.62±0.43. Cycle length change consistently with higher dose of ATRA.

CONCLUSION: This study has proven that ATRA could inhibit telomerase activity by lengthening the cycle. Changes in the increase of ATRA doses in this experimental test need to be studied further on experimental animals, either administered as a single agent or as an addition to standard treatment of trophoblastic disease.

Matched MeSH terms: Choriocarcinoma/drug therapy*; Choriocarcinoma/metabolism; Choriocarcinoma/pathology

A case report: metastatic choriocarcinoma to the gum

Shafiee MN, Ismail NM, Shan LP, Kampan N, Omar MH, Dali HM

Sex Reprod Healthc, 2011 Apr;2(2):91-2.

PMID: 21439527 DOI: 10.1016/j.srhc.2011.02.001

Choriocarcinoma is a rare neoplasia with a tendency of distant metastasis although highly sensitive to chemotherapy renders a good prognosis and outcome. Lungs, liver and cerebral metastasis are commonly implicated with maxillofacial region rarely involved. We illustrate a case of overwhelming metastatic choriocarcinoma to lungs, liver, brain and to the extreme of gum metastasis. Decompressive craniectomy for intracranial bleeding, multiple transfusions to correct anaemia and coagulopathy were done before high-risk-regime chemotherapy. Despite this, due to fulminant multi-organs involvement she finally succumbed to death. In conclusion, gum bleeding in choriocarcinoma may suggest metastasis and poor prognosis.

Matched MeSH terms: Choriocarcinoma/drug therapy; Choriocarcinoma/pathology*

Normal pregnancy after successful treatment of choriocarcinoma with cerebral metastases. A case report

Sivanesaratnam V, Sen DK

J Reprod Med, 1988 Apr;33(4):402-3.

PMID: 2452881

Pregnancy after treatment of choriocarcinoma with cerebral metastases is uncommon. We treated a patient successfully with less-toxic chemotherapeutic agents than those advocated by others together with whole brain irradiation. She subsequently had two uneventful pregnancies.

Matched MeSH terms: Choriocarcinoma/secondary; Choriocarcinoma/therapy*

Oral carcinoma in the first three decades of life

Ramanathan K

Med J Malaya, 1972 Sep;27(1):20-6.

PMID: 4345644

Matched MeSH terms: Choriocarcinoma/epidemiology; Choriocarcinoma/pathology

Fulltext Malignant ovarian mixed germ cell tumour: a rare combination

Koshy M, Vijayananthan A, Vadiveloo V

Biomed Imaging Interv J, 2005 Oct;1(2):e10.

PMID: 21625278 MyJurnal DOI: 10.2349/biij.1.2.e10

Ovarian germ cell tumours are very rare and affect mainly young girls and women. Due to this, the conservation of reproductive potential is of great concern. One of the most remarkable advances in oncology is in the treatment of malignant ovarian germ cell tumours. Two histological groups are distinguished: dygerminomas, equivalent to testicular seminomas, and non-dysgerminomatous tumours. We report a case of a 30-year-old nulliparous woman who presented with persistent per vaginal bleeding and was found to have a malignant mixed germ cell tumour comprising of both embryonal carcinoma and choriocarcinoma.

Matched MeSH terms: Choriocarcinoma

Displaying publications 1 - 20 of 27 in total